Literature DB >> 9074894

Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation.

Y M Irshaid1, H F al-Hadidi, A Latif, F Awwadi, M al-Zoubi, N M Rawashdeh.   

Abstract

The concentrations of dextromethorphan (DM) and its metabolites dextrorphan (DRP), 3-methoxymorphinan (MM) and 3-hydroxymorphinan (HM) were measured in 8 h urine samples from 266 unrelated healthy Jordanian subjects following oral administration of 30 mg dextromethorphan hydrobromide and using a rapid, sensitive and precise HPLC method with fluorometric detection. The frequency of the 'poor' metabolizer status of DM-O-demethylation as judged by log DM/DRP was found to be 6.8% with a 95% confidence interval of 3.8-9.8%. There was a strong correlation between log DM/DRP and log total non-O-demethylated compounds (NODM)/total O-demethylated metabolites (ODM) metabolic ratios (r = 0.96, P < 0.01). However, one subject with log DM/DRP of 0.05 that classifies him as a poor metabolizer was found to have a log NODM/ODM of -0.73 which is in the range of extensive metabolizer status suggesting the presence of another cytochrome P450 isoenzyme involved in dextromethorphan O-demethylation. Dextromethorphan N-demethylation to 3-methoxymorphinan was detected in 55.3% of individuals. Furthermore, a dissociation between dextromethorphan O-demethylation and debrisoquine (D) 4-hydroxylation has been observed. Among the 116 subjects phenotyped with both dextromethorphan and debrisoquine, 7 were poor metabolizers of both, three were poor metabolizers of debrisoquine and extensive metabolizers of dextromethorphan whilst 4 were poor metabolizers of dextromethorphan and extensive metabolizers of debrisoquine, one of whom was reclassified as an extensive metabolizer of dextromethorphan using log NODM/ODM to characterize dextromethorphan metabolizer status.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9074894     DOI: 10.1007/BF03189731

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  23 in total

1.  Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism.

Authors:  A Küpfer; B Schmid; R Preisig; G Pfaff
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

2.  CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans.

Authors:  E Jacqz-Aigrain; C Funck-Brentano; T Cresteil
Journal:  Pharmacogenetics       Date:  1993-08

3.  Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians.

Authors:  H F al-Hadidi; Y M Irshaid; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors:  B Schmid; J Bircher; R Preisig; A Küpfer
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

5.  Debrisoquine and metoprolol oxidation in Zambians: a population study.

Authors:  O O Simooya; E Njunju; A R Hodjegan; M S Lennard; G T Tucker
Journal:  Pharmacogenetics       Date:  1993-08

6.  Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver.

Authors:  F Broly; C Libersa; M Lhermitte; P Bechtel; B Dupuis
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

7.  The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.

Authors:  N L Kerry; A A Somogyi; F Bochner; G Mikus
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

8.  Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man.

Authors:  Z R Chen; A A Somogyi; F Bochner
Journal:  Ther Drug Monit       Date:  1990-01       Impact factor: 3.681

9.  Determination of dextromethorphan metabolizer phenotype in healthy volunteers.

Authors:  M Hildebrand; W Seifert; A Reichenberger
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

10.  Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man.

Authors:  M G Ladona; B Lindström; C Thyr; P Dun-Ren; A Rane
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

View more
  1 in total

1.  Metabolic capacity of CYP2D6 within an Iranian population (Mazandaran Province).

Authors:  Mohammad Reza Shiran; Fatemeh Sarzare; Fatemeh Merat; Ebrahim Salehifar; Ali Akbar Moghadamnia; Seyed Mohammad Bagher Hashemi Soteh
Journal:  Caspian J Intern Med       Date:  2011
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.